Vericel (VCEL) Share-based Compensation (2010 - 2026)
Vericel's (VCEL) quarterly Share-based Compensation came in at $11.3 million in Q1 2026, down 1.83% year-on-year from $11.5 million in Q1 2025, and up 34.09% quarter-over-quarter from $8.4 million in Q4 2025.
Vericel (VCEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Vericel has disclosed Share-based Compensation across 17 years of filings, most recently posting $11.3 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $11.3 million, down 1.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.6 million (up 1.02% YoY), and the FY2025 annual result was $38.8 million, up 6.23% from the prior year.
- Share-based Compensation came in at $11.3 million for Q1 2026 at Vericel, up from $8.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $11.5 million in Q1 2025 to a low of $6.9 million in Q4 2023.
- The 5-year median for Share-based Compensation is $9.1 million (2022), against an average of $9.2 million.
- Across the five-year window, Share-based Compensation surged 35.79% in 2022 and retreated 18.94% in 2023, its largest moves.
- Vericel's Share-based Compensation stood at $7.7 million in 2022, then fell by 10.74% to $6.9 million in 2023, then advanced by 14.59% to $7.9 million in 2024, then climbed by 6.39% to $8.4 million in 2025, then surged by 34.09% to $11.3 million in 2026.
- The last three Share-based Compensation figures came in at $11.3 million (Q1 2026), $8.4 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 11.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.29 Mn |
| Mar 31, 2026 | 11.29 Mn |
| Dec 31, 2025 | 8.42 Mn |
| Dec 31, 2025 | 8.42 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Jun 30, 2025 | 10.14 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Dec 31, 2024 | 7.92 Mn |
| Dec 31, 2024 | 7.92 Mn |
| Sep 30, 2024 | 9.22 Mn |
| Sep 30, 2024 | 9.22 Mn |
| Jun 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 9.52 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | 6.91 Mn |
| Dec 31, 2023 | 6.91 Mn |